Blog
RSS FeedPosted by Michael Wonder on 18 Mar 2022
Public summary documents – November 2021 PBAC meeting (first time rejections and deferrals)
18 March 2022 - The Public Summary Documents (first time rejections and deferrals) from the November 2021 PBAC meeting are now ...
Posted by Michael Wonder on 15 Mar 2022
Better care and treatment for Australians with blood cancer
15 March 2022 - Australians with blood cancer will receive improved treatment and care through new and continued funding from the ...
Posted by Michael Wonder on 15 Mar 2022
1 April 2022 price disclosure confirmed prices
15 March 2022 - Confirmed 1 April 2022 prices resulting from the 2022 April cycle of price disclosure have now been ...
Posted by Michael Wonder on 04 Mar 2022
Public summary documents – November 2021 PBAC meeting
4 March 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2021 PBAC ...
Posted by Michael Wonder on 02 Mar 2022
BeiGene hits major milestone with first PBS approved cancer treatment
1 March 2022 - BeiGene is welcoming the listing of Brukinsa (zanubrutinib), a targeted treatment for mantle cell lymphoma, an aggressive ...
Posted by Michael Wonder on 02 Mar 2022
Pharmaceutical Benefits Scheme: Pharmacy Guild of Australia say medication becoming unaffordable
1 March 2022 - A western Sydney pharmacist said Australians take pride in a universal healthcare system but “the universe doesn’t ...
Posted by Michael Wonder on 01 Mar 2022
New PBS listings from 1 March 2022
1 March 2022 - Australians will have access to four new medicines through the Pharmaceutical Benefits Scheme from March 1 to ...
Posted by Michael Wonder on 28 Feb 2022
Lagevrio (molnupiravir) PBS listing
1 March 2022 - Commencing 1 March 2022, Lagevrio (molnupiravir) will be listed on the PBS Section 85 program as an ...
Posted by Michael Wonder on 28 Feb 2022
Schedule of Pharmaceutical Benefits - 1 March 2022
1 March 2022 - The March 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 26 Feb 2022
Landmark PBS listing for Australians with leukaemia
25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 25 Feb 2022
PBAC recommendation for molnupiravir (Lagevrio)
25 February 2022 - The PBAC undertook an expedited consideration of a sponsor submission (MSD) to add molnupiravir (Lagevrio) to the ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 22 Feb 2022
Does the DoH favour some pharmaceutical companies over others?
23 February 2022 - Some interesting insights from version 1 of the agenda for the May 2022 PBAC (intracycle) meeting. ...
Posted by Michael Wonder on 21 Feb 2022
PBS arrangements for medicines for the treatment of paroxysmal nocturnal haemoglobinuria
21 February 2022 - Commencing 1 March 2022, Soliris (eculizumab) and Ultomiris (ravulizumab) will be listed on the Pharmaceutical Benefits Scheme ...